These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9035702)

  • 21. Pharmacologic profile of tazarotene.
    Duvic M
    Cutis; 1998 Feb; 61(2 Suppl):22-6. PubMed ID: 9787988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of tazarotene in the treatment of psoriasis.
    Marks R
    Br J Dermatol; 1999 Apr; 140 Suppl 54():24-8. PubMed ID: 10731131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
    Tzung TY; Wu JC; Hsu NJ; Chen YH; Ger LP
    Acta Derm Venereol; 2005; 85(3):236-9. PubMed ID: 16040409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging.
    Roeder A; Schaller M; Schäfer-Korting M; Korting HC
    Skin Pharmacol Physiol; 2004; 17(3):111-8. PubMed ID: 15087589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks.
    Weinstein GD; Koo JY; Krueger GG; Lebwohl MG; Lowe NJ; Menter MA; Lew-Kaya DA; Sefton J; Gibson JR; Walker PS;
    J Am Acad Dermatol; 2003 May; 48(5):760-7. PubMed ID: 12734506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
    J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis].
    Sander P; Happe M; Stücker M; Hermes N; Hoffmann K; Altmeyer P
    Hautarzt; 1999 Oct; 50(10):723-7. PubMed ID: 10550358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
    Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
    J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.
    Tanghetti EA;
    Cutis; 2000 Dec; 66(6 Suppl):4-11. PubMed ID: 11147088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tazarotene-loaded
    Erol İ; Üstündağ Okur N; Orak D; Sipahi H; Aydın A; Özer Ö
    Pharm Dev Technol; 2020 Oct; 25(8):909-918. PubMed ID: 32364036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
    Poulin YP
    Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tazarotene in combination with topical corticosteroids.
    Lebwohl M; Poulin Y
    J Am Acad Dermatol; 1998 Oct; 39(4 Pt 2):S139-43. PubMed ID: 9777792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short contact therapy with tazarotene in psoriasis vulgaris.
    Veraldi S; Caputo R; Pacifico A; Peris K; Soda R; Chimenti S
    Dermatology; 2006; 212(3):235-7. PubMed ID: 16549919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical tazarotene: a review of its use in the treatment of plaque psoriasis.
    Dando TM; Wellington K
    Am J Clin Dermatol; 2005; 6(4):255-72. PubMed ID: 16060713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
    Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.
    Scher RK; Stiller M; Zhu YI
    Cutis; 2001 Nov; 68(5):355-8. PubMed ID: 11766122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tazarotene induces epidermal cell differentiation in the mouse tail test used as an animal model for psoriasis.
    Sebök B; Bonnekoh B; Kerényi M; Gollnick H
    Skin Pharmacol Appl Skin Physiol; 2000; 13(5):285-91. PubMed ID: 10940819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (Zorac TM).
    Gollnick HP; Finzi AF; Marks R; Barker JN; Jansen C; Revuz J; Saurat J
    Dermatology; 1999; 199(1):40-6. PubMed ID: 10449956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Periungual pyogenic granulomas due to topical tazarotene for nail psoriasis.
    Piraccini BM; Venturi M; Patrizi A
    G Ital Dermatol Venereol; 2014 Jun; 149(3):363-6. PubMed ID: 24819765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.